Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Considering Biotech Acquisitions; “Probably No” Big Mergers

Executive Summary

Pfizer is returning to acquisition mode, but with an eye on building its biotechnology presence rather than another major pharmaceutical merger

You may also be interested in...



UCB Acquiring Celltech; Phase III TNF Inhibitor At Center Of $2.7 Bil. Deal

UCB is paying $2.7 bil. to lock up rights to Celltech's TNF inhibitor CDP-870

UCB Acquiring Celltech; Phase III TNF Inhibitor At Center Of $2.7 Bil. Deal

UCB is paying $2.7 bil. to lock up rights to Celltech's TNF inhibitor CDP-870

Pfizer Recognizes “Dark Side” Of Scale In R&D; No Sales Force Cuts Planned

Pfizer relies on competition among research teams to help ensure that its vast R&D resources do not diminish the entrepreneurial spirit within the organization, CFO David Shedlarz told the Merrill Lynch pharmaceutical and biotechnology conference Feb. 5 in New York City

Related Content

UsernamePublicRestriction

Register

PS042843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel